TY - JOUR
T1 - Identifying and targeting angiogenesis-related microRNAs in ovarian cancer
AU - Chen, Xiuhui
AU - Mangala, Lingegowda S.
AU - Mooberry, Linda
AU - Bayraktar, Emine
AU - Dasari, Santosh K.
AU - Ma, Shaolin
AU - Ivan, Cristina
AU - Court, Karem A.
AU - Rodriguez-Aguayo, Cristian
AU - Bayraktar, Recep
AU - Raut, Sangram
AU - Sabnis, Nirupama
AU - Kong, Xianchao
AU - Yang, Xianbin
AU - Lopez-Berestein, Gabriel
AU - Lacko, Andras G.
AU - Sood, Anil K.
N1 - Funding Information:
Acknowledgements This work is supported, in part, by the National Institutes of Health (CA016672, UH3TR000943, P50 CA217685, P50 CA098258, R35 CA209904), Ovarian Cancer Research Fund, Inc. (Program Project Development Grant), Mr. and Mrs. Daniel P. Gordon, The Blanton-Davis Ovarian Cancer Research Program, the American Cancer Society Research Professor Award, and the Frank McGraw Memorial Chair in Cancer Research (AKS) and CPRIT (DP150091; LSM). SKD was supported by Foundation for Women’s Cancer Grant, CRA was supported by the P50 CA217685 from the SPORE in Ovarian Cancer at MD Anderson.
Publisher Copyright:
© 2019, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2019/8/15
Y1 - 2019/8/15
N2 - Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein–nanoparticles (rHDL–NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.
AB - Current anti-angiogenic therapy for cancer is based mainly on inhibition of the vascular endothelial growth factor pathway. However, due to the transient and only modest benefit from such therapy, additional approaches are needed. Deregulation of microRNAs (miRNAs) has been demonstrated to be involved in tumor angiogenesis and offers opportunities for a new therapeutic approach. However, effective miRNA-delivery systems are needed for such approaches to be successful. In this study, miRNA profiling of patient data sets, along with in vitro and in vivo experiments, revealed that miR-204-5p could promote angiogenesis in ovarian tumors through THBS1. By binding with scavenger receptor class B type 1 (SCARB1), reconstituted high-density lipoprotein–nanoparticles (rHDL–NPs) were effective in delivering miR-204-5p inhibitor (miR-204-5p-inh) to tumor sites to suppress tumor growth. These results offer a new understanding of miR-204-5p in regulating tumor angiogenesis.
UR - http://www.scopus.com/inward/record.url?scp=85068690084&partnerID=8YFLogxK
U2 - 10.1038/s41388-019-0862-y
DO - 10.1038/s41388-019-0862-y
M3 - Article
C2 - 31289363
AN - SCOPUS:85068690084
VL - 38
SP - 6095
EP - 6108
JO - Oncogene
JF - Oncogene
SN - 0950-9232
IS - 33
ER -